Navigation Links
Final Rules Broaden Pool for Stem Cell Research
Date:7/6/2009

Older stem cell lines eligible for U.S. research dollars, NIH says

MONDAY, July 6 (HealthDay News) -- The U.S. government issued final guidelines Monday describing which embryonic stem cell lines will be eligible for government funding, effectively expanding the universe of stem cells that can be used for research.

Going forward, researchers will have to demonstrate that embryonic stem cells used in research were obtained from fertility clinic embryos that otherwise would have been discarded. Also, the stem cells must come with the informed consent of the parents or mother.

But stem cells developed earlier will not require such precise documentation, representing a departure from draft guidelines issued in April by the U.S. National Institutes of Health.

According to published reports, earlier stem cell lines must meet the "spirit" of the new guidelines, if not the "letter," to qualify for taxpayer-supported funding.

The crucial test, The New York Times reported, is whether the embryos used to create the older stem cell lines were created for reproductive purposes and whether donors freely consented to their use in research procedures. At a news conference Monday, Dr. Raynard S. Kington, acting director of the NIH, noted that some researchers had used videos instead of written forms in the past and that such a minor difference in protocol would not make that research ineligible for financing, the newspaper said.

The new guidelines still ban federal financing for research on stem cell lines derived from embryos created solely for research.

In March, President Barack Obama signed an executive order that he said would allow federal taxpayer dollars to fund significantly broader research on embryonic stem cells because "medical miracles do not happen simply by accident."

The executive order overturned a long-standing Bush administration policy limiting government fund
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Nationwide Heat Wave Finally Gives Way To Cooling Trend
2. Finally, The Round Diet! A Diet Simple Enough that Even a Kindergartener Can Follow It
3. University of Maryland Company Trauma Solutions Named Finalist in $250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition
4. Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
5. Does Botox(R) Finally Have Competition?
6. Hard to Treat Diseases, Inc. (HTDS) Finalizes Agreement with Yunnan Walvax Biotech
7. InfoLogix CEO David Gulian Named Ernst & Young Entrepreneur Of The Year 2009 Award Finalist in Greater Philadelphia
8. FDA Accepts Final Section of NDA Filing for LUCASSIN(R)
9. Reliv International Named As Finalist In the American Business Awards
10. Social Entrepreneurs Cup Finalists Announced
11. Finalists Perform at Rock Hall in Rainbow Babies & Childrens Hospitals Pause to Click Contest Encouraging Safety Belt Use for Tweens
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 2Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 3Health News:AUL Action: Senate Health Bill Now Leads to Unprecedented Federal Abortion Funding 4Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 2Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 3Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 4Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 3Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 4Health News:New study finds low rate of injuries at overnight summer camp 2
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 1Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 11Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 12Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 13Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 14Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 15Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 16Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 17Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 18The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 1The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 1American Society of Plastic Surgeons hosts 78th annual meeting 58275 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 3